查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2004189

癌症支持治療藥物市場：2026-2032年全球市場預測（按藥物類別、癌症類型、給藥途徑、活性原料藥成分類型、年齡層、適應症、醫療機構、分銷管道和最終用戶分類）

Cancer Supportive Care Drugs Market by Drug Class, Cancer Type, Route Of Administration, Originator Type, Age Group, Indication, Care Setting, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，癌症支持治療藥物市場價值將達到 1.5379 億美元，到 2026 年將成長至 1.6403 億美元，到 2032 年將達到 2.4697 億美元，複合年成長率為 7.00%。

主要市場統計數據
基準年 2025 1.5379億美元
預計年份：2026年 1.6403億美元
預測年份 2032 2.4697億美元
複合年成長率 (%) 7.00%

現代腫瘤學越來越需要支持性護理，以維持治療的連續性並提高患者的生活品質。

癌症支持治療作為腫瘤治療的重要補充，其發展持續推進，重點在於維持患者功能、最大限度減少治療中斷，並在整個治療過程中提升患者的生活品質。化療技術的進步、對患者生存期的日益關注，以及對支持治療作為以價值為導向的癌症治療不可或缺組成部分的認可度不斷提高，共同推動了預防或減輕噁心、感染疾病、骨骼併發症、貧血和疼痛等副作用藥物的臨床和商業性價值的提升。隨著治療方法日益複雜，患者擴大在門診和家庭環境中接受治療，對有效支持治療藥物及其給藥模式的需求日益成長，促使相關人員重新審視藥物的可及性、依從性和整合式醫療服務路徑。

本研究檢驗了臨床、商業性和交付模式的轉變，這種轉變正在重新定義支持性照護策略和相關人員的獎勵。

癌症支持治療領域正經歷著一場變革性的轉變，其驅動力包括臨床創新、不斷演進的治療模式以及支付方優先事項的轉變，這些因素共同重塑了支持治療藥物的研發、應用和報銷方式。新型止吐策略和造血藥物的改進正在取得進展，同時，骨骼改良療法和鎮痛方案的多樣化也在不斷推進。所有這些都反映出人們對治療相關毒性和生存需求的理解更加深入。這些治療進展，加上生物相似藥和學名藥的擴張，迫使傳統製藥企業優先考慮生命週期管理、患者支持項目和基於價值的契約，以維護其臨床和商業性地位。

本研究評估了 2025 年價格政策轉變將如何改變支持性照護中所有相關人員的供應鏈動態、採購重點和取得途徑。

美國於2025年實施的政策變化和關稅調整，為整個支持性醫療生態系統帶來了新的營運和策略考量，其累積影響正波及到生產、分銷和醫療服務提供者等各個層面。影響進口活性藥物成分、製劑和醫療用品的關稅調整，凸顯了供應鏈圖譜和服務交付成本分析的重要性。製造商被迫重新評估其籌資策略，與替代供應商建立合作關係，並加快二級供應商的認證流程以降低風險。這種調整正在影響前置作業時間、庫存政策以及用於緊急生產能力的資金配置。

整合多維細分可以揭示整個支持性護理市場的臨床重點、產品差異化和分銷策略。

透過對藥物類別、癌症類型、給藥途徑、原料藥成分類型、年齡層、適應症、醫療機構、分銷管道和最終用戶進行細分，可以建立一個多維地圖，從而了解臨床需求、商業性機會和營運限制的交匯點。在藥物類別內部，止吐藥、骨骼調節劑、造血劑和止痛藥分別針對不同的臨床問題。止吐藥類別本身包含多種藥理學亞類，例如 5-HT3 受體拮抗劑、NK1 受體拮抗劑和Olanzapine；骨骼調節療法包括雙磷酸鹽和 RANKL 抑制劑；造血支持療法包括促紅細胞生成素、骨髓保護劑和血小板生成素促效劑，其中促紅細胞生成素的典型製劑包括Darbepoetin和促紅血球生成貝泊素。疼痛管理分為非鴉片類藥物療法和鴉片類藥物療法，非鴉片類藥物療法又以對乙醯胺酚、輔助鎮痛藥和非類固醇消炎劑為特徵。

本文比較了各大地區的監管、報銷和供應實踐，以指導差異化的准入和商業化策略。

區域趨勢影響著輔助治療藥物的研發、核准和交付，每個區域都有其獨特的法規環境、報銷框架和醫療基礎設施。在美洲，先進的腫瘤治療網路和完善的臨床試驗體系與支付主導的成本控制措施並存，迫使製藥公司在創新與可負擔性之間尋求平衡，並投資於全面的患者支持和療效證據。向門診和居家照護的轉變意義重大，推動了對口服製劑、皮下注射劑型以及能夠實現遠端監測和用藥依從性支持的服務的需求。

分析製藥公司、專業醫療保健提供者和技術合作夥伴在塑造支持性護理服務方面的策略角色和競爭動態。

關鍵產業相關人員包括原廠藥公司、生物相似藥生產商、學名藥生產商、專科藥房、契約製造組織 (CMO) 和醫療技術提供商，它們各自為支持性醫療價值鏈帶來獨特的優勢。原廠藥公司持續利用臨床差異化、緩釋製劑和整合式病患服務來保護其現有產品組合。同時，生物相似藥和學名藥參與企業透過提供更低成本的替代方案並與批發商和專科經銷商建立策略合作夥伴關係，加劇了競爭壓力。專科藥局和整合式醫療服務提供者在協調家庭靜脈輸液治療、監測用藥依從性和病患教育方面發揮日益重要的作用，成為確保支持性醫療連續性的關鍵環節。

優先採取與證據生成、供應鏈韌性、擴大患者支持和靈活合約相關的策略措施，以確保競爭優勢。

在不斷變化的輔助治療領域，行業領導者應優先採取一系列切實可行的措施，以確保患者能夠獲得所需服務，最佳化治療效果，並維持商業性的永續性。首先，將可靠的真實世界數據 (RWE) 的創建納入產品項目，以證明其在臨床上能夠顯著減少住院次數、治療中斷和輔助治療負擔，從而促進支付方的參與，並支持基於價值的協議。其次，透過供應商多元化、盡可能採用近岸外包以及製定緊急庫存計畫來增強供應鏈韌性，從而降低政策變革和物流中斷帶來的風險。第三，拓展病患支援服務，包括經濟援助、遠端監測和客製化的家庭管理，以提高病患的用藥依從性和滿意度，同時增強產品差異化優勢。

採用混合方法，結合臨床文獻、專家訪談和交叉檢驗分析，為支持性照護提供實務見解。

本研究整合了多種方法，旨在整合與支持性治療相關的臨床、營運和商業性見解。為建立實證基礎，本研究首先對同儕審查的臨床文獻、監管指導文件、公共公告和權威臨床實踐調查方法進行了全面的二次研究。為補充此基準，本研究還開展了一項初步調查，包括對腫瘤科臨床醫生、專科藥劑師、醫療系統處方集決策者、保險公司和行業高管進行結構化訪談，以了解他們對臨床未滿足需求、獲取障礙和商業化策略的實際觀點。

本文總結了臨床、營運和商業策略的整合如何決定不斷發展的支持性護理生態系統中的准入和治療結果。

這些分析凸顯了支持性治療藥物在現代腫瘤治療實務中的核心作用，它們影響著治療的連續性、病患體驗和醫療資源的利用。臨床創新以及向門診和居家照護模式的轉變，對藥物製劑、物流和患者支援提出了更高的要求。同時，政策趨勢和定價考量也帶來了新的營運限制，需要在採購、分銷和定價方面進行策略調整。能夠整合嚴謹的真實世界數據、建立穩健的供應鏈以及以患者為中心的服務模式，從而向保險公司、醫療服務提供者和患者展現價值的利益相關人員者，才能最終獲得成功。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：癌症支持治療藥物市場：依藥物類別分類

  • 止吐藥
    • 5-HT3拮抗劑
    • NK1拮抗劑
    • Olanzapine
  • 骨骼調節藥物
    • 雙磷酸鹽
    • RANKL抑制劑
  • 造血因子
    • 促紅細胞生成素
      • Darbepoetin
      • 促紅素
    • 骨髓保護劑
    • 血小板生成素受體促效劑
  • 疼痛管理藥物
    • 非鴉片類藥物
      • 乙醯胺酚
      • 輔助止痛藥
      • 非類固醇消炎劑（NSAIDs）
    • 鴉片類藥物

第9章 癌症支持治療藥物市場：依癌症類型分類

  • 骨髓惡性腫瘤
    • 白血病
    • 淋巴瘤
    • 多發性骨髓瘤
    • 骨髓發育不良症候群
  • 固體癌
    • 乳癌
    • 結腸癌
    • 胃腸道癌症
    • 頭頸癌
    • 肺癌
    • 卵巢癌
    • 攝護腺癌

第10章：癌症支持治療藥物市場：依給藥途徑分類

  • 靜脈
  • 口服
  • 直腸
  • 皮下
  • 外用
  • 經皮

第11章 癌症支持治療藥物市場：依原料藥類型分類

  • 生物相似藥
  • 品牌商品
  • 非專利的

第12章：癌症支持治療藥物市場：依年齡層別分類

  • 成人版
  • 老年人
  • 兒童

第13章：癌症支持治療藥物市場：依適應症分類

  • 與骨轉移相關的事件
  • 惡病質和食慾不振
  • 癌症疼痛
  • 化療引起的噁心和嘔吐
    • 急性化療引起的噁心嘔吐
    • 特發性/難治性化療引起的噁心嘔吐
    • 延遲性 CINV
  • 腹瀉
  • 黏膜炎和口腔炎
  • 骨髓抑制
    • 化療引起的貧血
    • 化療引起的嗜中性白血球低下症

第14章：癌症支持治療藥物市場：依臨床環境分類

  • 住院病人
  • 門診

第15章：癌症支持治療藥物市場：按分銷管道分類

  • 醫院藥房
  • 郵購及網路藥房
  • 零售藥房
  • 專科藥房

第16章 癌症支持治療藥物市場：依最終用戶分類

  • 門診手術中心
  • 居家醫療
  • 醫院
  • 腫瘤診所和輸液中心

第17章 癌症支持治療藥物市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第18章：癌症支持治療藥物市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第19章 癌症支持治療藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第20章：美國：癌症支持治療藥物市場

第21章 中國：癌症支持治療藥物市場

第22章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Acacia Pharma Group Plc
  • Accord Healthcare Limited
  • Amgen Inc.
  • APR Applied Pharma Research SA by Relief Therapeutics Holding AG
  • AstraZeneca plc
  • Coherus BioSciences, Inc.
  • Daiichi Sankyo Company, Limited
  • Dr. Reddy's Laboratories Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Fresenius Kabi AG
  • Fresenius SE & Co. KGaA
  • GlaxoSmithKline plc
  • Helsinn Healthcare SA
  • Heron Therapeutics, Inc.
  • Ipsen SA
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: MRR-450A0628C601

The Cancer Supportive Care Drugs Market was valued at USD 153.79 million in 2025 and is projected to grow to USD 164.03 million in 2026, with a CAGR of 7.00%, reaching USD 246.97 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 153.79 million
Estimated Year [2026] USD 164.03 million
Forecast Year [2032] USD 246.97 million
CAGR (%) 7.00%

Framing the evolving imperative for supportive therapies that preserve treatment continuity and enhance patient quality of life across modern oncology care

Cancer supportive care continues to evolve as a critical complement to oncologic therapy, focusing on preserving patient function, minimizing treatment interruptions, and improving quality of life across the treatment continuum. Advances in anticancer therapeutics, rising emphasis on survivorship, and broader recognition of supportive care as an integral component of value-based oncology care have collectively elevated the clinical and commercial importance of drugs that prevent or mitigate adverse effects such as nausea, infection, bone complications, anemia, and pain. As treatment regimens become more complex and patients increasingly receive therapy in outpatient or home settings, the need for effective supportive agents and delivery models has intensified, prompting stakeholders to re-examine pathways for access, adherence, and integrated care delivery.

Regulatory attention and payer scrutiny have shifted the conversation from episodic symptom control to longitudinal management strategies that reduce hospitalizations and enable continued cancer-directed therapy. Meanwhile, technological enablers such as telemedicine, remote monitoring, and digital adherence tools are being woven into supportive care pathways to detect complications early and to triage interventions. These developments are influencing clinical practice guidelines, hospital formularies, and procurement strategies, while simultaneously shaping expectations among patients and caregivers for a higher standard of symptom management. Consequently, supportive care drugs are no longer ancillary commodities but constitute strategic assets in optimizing treatment outcomes and sustaining healthcare system efficiencies.

Examining the clinical, commercial, and delivery model transformations that are redefining supportive care strategies and stakeholder incentives

The landscape of cancer supportive care has undergone transformative shifts driven by clinical innovation, delivery model changes, and evolving payer priorities that collectively reshape how supportive medicines are developed, adopted, and reimbursed. Novel antiemetic strategies and refinements in hematopoietic agents are emerging alongside an expanding portfolio of bone-modifying therapies and diversified analgesic options, all of which reflect a more nuanced understanding of treatment-related toxicities and survivorship needs. These therapeutic advances are complemented by an expansion of biosimilars and generics that force incumbent manufacturers to prioritize lifecycle management, patient support programs, and value-based contracting to defend clinical and commercial positioning.

Concurrent shifts in care delivery have profound implications. An acceleration of outpatient infusion, homecare services, and remote monitoring has prompted manufacturers and providers to redesign packaging, dosing regimens, and adherence support to accommodate decentralized treatment environments. Payer emphasis on outcomes and cost containment is incentivizing real-world evidence generation and performance-based agreements, which in turn influence clinical guideline adoption and formulary decisions. Supply chain resilience and manufacturing flexibility have become strategic priorities in light of geopolitical pressures and episodic disruptions, increasing interest in diversified sourcing, nearshoring, and capacity partnering with contract manufacturers. Taken together, these shifts signal a more integrated, multidisciplinary approach to supportive care that aligns clinical efficacy with operational feasibility and economic sustainability.

Assessing how tariff policy shifts in 2025 altered supply chain dynamics, procurement priorities, and access pathways across supportive care stakeholders

Policy changes and tariff considerations introduced in the United States in 2025 have injected a new set of operational and strategic calculations across the supportive care ecosystem, with cumulative impacts felt at the manufacturing, distribution, and provider levels. Tariff adjustments affecting imported active pharmaceutical ingredients, finished formulations, and medical supplies have increased the emphasis on supply chain mapping and cost-to-serve analysis. Manufacturers have been prompted to reassess sourcing strategies, pursue alternative supplier relationships, and accelerate qualification of secondary suppliers to mitigate exposure. This recalibration has implications for lead times, inventory policies, and capital allocation for contingency manufacturing capacity.

These policy-induced cost pressures have reverberated through distribution channels and procurement cycles, elevating negotiation intensity between manufacturers, distributors, and payers. Health systems and specialty pharmacies have intensified their focus on formulary optimization and total cost-of-care calculations to preserve access while managing budgets. At the clinical interface, providers have become more attentive to therapeutic equivalence and to opportunities for substituting lower-cost generics or biosimilars where clinically appropriate. Patient support mechanisms have also been affected as companies re-evaluate copay assistance programs and logistical support for home administration to ensure affordability and continuity of therapy.

In response to tariff-driven uncertainty, some stakeholders have advocated for policy engagement and collaborative solutions, such as tariff exemptions for critical medical inputs, incentives for domestic manufacturing, and streamlined regulatory pathways for rapid supplier qualification. These strategies aim to balance the goals of national industrial policy with the imperative to maintain patient access and clinical quality. Looking ahead, organizations that proactively adapt procurement, contractual frameworks, and patient support models will be better positioned to navigate sustained policy variability while safeguarding treatment continuity for vulnerable patient populations.

Integrating multi-dimensional segmentation to illuminate clinical priorities, product differentiation, and distribution strategies across supportive care markets

Segmentation across drug class, cancer type, route of administration, originator type, age group, indication, care setting, distribution channel, and end user creates a multidimensional map for understanding where clinical needs intersect with commercial opportunity and operational constraints. Within drug class, antiemetics, bone-modifying agents, hematopoietic agents, and pain management agents each address distinct clinical problems; the antiemetic category itself includes pharmacologic subclasses such as 5-HT3 antagonists, NK1 antagonists, and olanzapine, while bone-modifying therapies encompass bisphosphonates and RANKL inhibitors. Hematopoietic support spans erythropoiesis stimulating agents, myeloprotection agents, and thrombopoietin receptor agonists, and erythropoiesis stimulating agents are characterized by formulations such as darbepoetin and epoetin. Pain management divides into non-opioid and opioid approaches, with non-opioids further characterized by acetaminophen, adjuvant analgesics, and nonsteroidal anti-inflammatory drugs.

Cancer type segmentation distinguishes hematologic malignancies and solid tumors, with hematologic categories covering leukemias, lymphomas, multiple myeloma, and myelodysplastic syndromes, while solid tumors include breast, colorectal, gastrointestinal, head and neck, lung, ovarian, and prostate cancers, each of which presents unique supportive care priorities and guideline-driven interventions. Route of administration intersects with care setting considerations, spanning intravenous, oral, rectal, subcutaneous, topical, and transdermal modalities, and prompting different patient education, adherence, and logistics needs. Originator type-biosimilar, branded, and generic-shapes pricing dynamics and contracting strategies, while age-group segmentation across adult, geriatric, and pediatric populations demands tailored dosing, safety monitoring, and caregiver support.

Indication-based segmentation addresses complications such as bone metastases related events, cachexia and anorexia, cancer pain, chemotherapy-induced nausea and vomiting with its acute, breakthrough/refractory, and delayed subcategories, diarrhea, mucositis and stomatitis, and myelosuppression including chemotherapy-induced anemia and neutropenia; each indication imposes specific efficacy, safety, and delivery expectations. Distribution channel and end-user segmentation illuminate commercial pathways, with hospital pharmacies, mail-order and online pharmacies, retail pharmacies, and specialty pharmacies interacting with ambulatory surgery centers, homecare settings, hospitals, and oncology clinics and infusion centers. Integrating these segmentation lenses enables stakeholders to prioritize product development, align patient support programs, and design distribution strategies that reflect clinical workflows and payer requirements.

Comparing the regulatory, reimbursement, and delivery realities across major regions to guide differentiated access and commercialization strategies

Regional dynamics shape how supportive care drugs are developed, approved, and delivered, with each geography presenting distinct regulatory environments, reimbursement paradigms, and care delivery infrastructures. In the Americas, advanced oncology care networks and strong clinical trial ecosystems coexist with payer-driven cost containment, driving manufacturers to balance innovation with affordability and to invest in robust patient support and outcomes evidence. Shifts toward outpatient and home-based care are pronounced, amplifying demand for oral formulations, subcutaneous options, and services that enable remote monitoring and adherence support.

In Europe, Middle East & Africa, heterogeneous regulatory frameworks and diverse market access pathways require differentiated strategies that account for national reimbursement rules, tendering mechanisms, and varying levels of healthcare infrastructure. Manufacturers often pursue regionally tailored evidence generation and pricing strategies to secure formulary inclusion, and partnerships with regional distributors and specialty pharmacies are common to bridge logistical gaps and enhance reach. In the Asia-Pacific region, rapid healthcare modernization, expanding oncology service capacity, and growing attention to biosimilar adoption create both opportunities and complexities. Regulatory harmonization efforts coexist with country-specific procurement models, and manufacturers are incentivized to develop flexible supply arrangements and locally relevant patient support services to accelerate uptake and sustain access amid evolving payer expectations.

Profiling the strategic roles and competitive moves of manufacturers, specialty providers, and technology partners shaping supportive care delivery

Key industry participants span originator pharmaceutical companies, biosimilar manufacturers, generic producers, specialty pharmacies, contract manufacturing organizations, and healthcare technology providers, each contributing distinct capabilities to the supportive care value chain. Originator firms continue to leverage clinical differentiation, extended-release formulations, and integrated patient services to defend established franchises, while biosimilar and generic entrants intensify competitive pressure by offering lower-cost alternatives and by pursuing strategic partnerships with wholesalers and specialty distributors. Specialty pharmacies and integrated care providers play an increasingly important role in coordinating home infusion, adherence monitoring, and patient education, serving as critical touchpoints for ensuring continuity of supportive therapy.

Contract manufacturing and outsourcing partners have expanded capacity to meet demand for flexible production and regulatory compliance, enabling companies to respond more rapidly to supply disruptions and to local content requirements. Technology providers supplying remote monitoring, telehealth platforms, and digital adherence tools are forging collaborations with manufacturers and providers to support decentralized care models. Across this ecosystem, leading organizations are distinguishing themselves through investments in real-world evidence, comprehensive patient support programs that address affordability and logistics, and value-based contracting approaches that align reimbursement with clinical outcomes. These strategic moves reflect a broader emphasis on integrated care pathways, where drug efficacy must be matched by delivery capabilities and demonstrable impact on patient-relevant endpoints.

Prioritizing strategic actions on evidence generation, supply chain resilience, patient support expansion, and flexible contracting to secure competitive advantage

Industry leaders should prioritize a set of actionable initiatives to secure access, optimize patient outcomes, and sustain commercial viability in a changing supportive care environment. First, embedding robust real-world evidence generation into product programs will facilitate payer engagement and support value-based agreements by demonstrating clinically meaningful reductions in hospitalizations, treatment interruptions, and supportive care burden. Second, strengthening supply chain resilience through supplier diversification, nearshoring where feasible, and contingency inventory planning will reduce vulnerability to policy shifts and logistic disruptions. Third, expanding patient support services that encompass financial navigation, remote monitoring, and coordinated home administration will improve adherence and patient satisfaction while reinforcing differentiation.

In parallel, organizations should adopt flexible pricing and contracting frameworks that account for total cost of care and enable outcome-based arrangements with payers and providers. Product teams must align formulation development and packaging innovations with the realities of outpatient and home care to enhance usability and safety. Strategic alliances with specialty pharmacies, homecare providers, and technology vendors can accelerate adoption of decentralized care models and provide seamless patient experiences. Executing these recommendations requires cross-functional coordination across commercial, medical, regulatory, and supply chain teams, and a willingness to pilot new commercial models in partnership with payers and provider systems to generate the evidence and operational learnings necessary for scale.

Explaining the mixed-methods approach that combines clinical literature, expert interviews, and cross-validated analysis to produce actionable supportive care insights

This research integrates a multi-method approach to synthesize clinical, operational, and commercial insights relevant to supportive care therapeutics. The methodology begins with comprehensive secondary research drawn from peer-reviewed clinical literature, regulatory guidance documents, public policy announcements, and authoritative clinical practice guidelines to establish an evidence-based foundation. This baseline was complemented by primary research consisting of structured interviews with oncology clinicians, specialty pharmacists, health system formulary decision-makers, payers, and industry executives to capture frontline perspectives on clinical unmet needs, access barriers, and commercialization tactics.

Analytical methods included qualitative thematic analysis to surface recurring themes and strategic priorities, and cross-validation using triangulation across data sources to ensure consistency and reduce bias. Segmentation frameworks were constructed by mapping therapeutic classes, clinical indications, administration routes, and care settings to real-world care pathways, allowing for scenario analysis of distribution and access models. Validation steps involved iterative review with independent clinical advisors and supply chain specialists to refine assumptions about operational feasibility and to corroborate strategic interpretations. Where applicable, regulatory and policy analyses were incorporated to contextualize potential impacts on procurement, manufacturing, and patient access.

Summarizing how integrated clinical, operational, and commercial strategies will determine access and outcomes in the evolving supportive care ecosystem

The cumulative analysis underscores that supportive care drugs are central to contemporary oncology practice, influencing treatment continuity, patient experience, and healthcare resource utilization. Clinical innovation, coupled with shifts in care delivery toward outpatient and home-based models, has elevated requirements for formulations, logistics, and patient support. Concurrently, policy developments and tariff considerations have introduced new operational constraints that necessitate strategic adaptation across sourcing, distribution, and pricing. Stakeholders that succeed will be those that integrate rigorous real-world evidence, resilient supply chains, and patient-centric service models to demonstrate value to payers, providers, and patients.

Looking ahead, the convergence of clinical, commercial, and operational trends points to a future in which supportive care strategies are tightly aligned with broader oncology objectives: enabling sustained delivery of cancer-directed therapies, mitigating adverse events, and optimizing total cost of care. Organizations that proactively reconfigure their portfolios, partnerships, and evidence-generation strategies to reflect decentralized care realities and evolving reimbursement expectations will be best positioned to deliver meaningful improvements in patient outcomes while sustaining long-term competitiveness.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cancer Supportive Care Drugs Market, by Drug Class

  • 8.1. Antiemetics
    • 8.1.1. 5-HT3 Antagonists
    • 8.1.2. NK1 Antagonists
    • 8.1.3. Olanzapine
  • 8.2. Bone-Modifying Agents
    • 8.2.1. Bisphosphonates
    • 8.2.2. RANKL Inhibitors
  • 8.3. Hematopoietic Agents
    • 8.3.1. Erythropoiesis Stimulating Agents
      • 8.3.1.1. Darbepoetin
      • 8.3.1.2. Epoetin
    • 8.3.2. Myeloprotection Agents
    • 8.3.3. Thrombopoietin Receptor Agonists
  • 8.4. Pain Management Agents
    • 8.4.1. Non-Opioids
      • 8.4.1.1. Acetaminophen
      • 8.4.1.2. Adjuvant Analgesics
      • 8.4.1.3. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
    • 8.4.2. Opioids

9. Cancer Supportive Care Drugs Market, by Cancer Type

  • 9.1. Hematologic Malignancies
    • 9.1.1. Leukemias
    • 9.1.2. Lymphomas
    • 9.1.3. Multiple Myeloma
    • 9.1.4. Myelodysplastic Syndromes
  • 9.2. Solid Tumors
    • 9.2.1. Breast Cancer
    • 9.2.2. Colorectal Cancer
    • 9.2.3. Gastrointestinal Cancers
    • 9.2.4. Head And Neck Cancer
    • 9.2.5. Lung Cancer
    • 9.2.6. Ovarian Cancer
    • 9.2.7. Prostate Cancer

10. Cancer Supportive Care Drugs Market, by Route Of Administration

  • 10.1. Intravenous
  • 10.2. Oral
  • 10.3. Rectal
  • 10.4. Subcutaneous
  • 10.5. Topical
  • 10.6. Transdermal

11. Cancer Supportive Care Drugs Market, by Originator Type

  • 11.1. Biosimilar
  • 11.2. Branded
  • 11.3. Generic

12. Cancer Supportive Care Drugs Market, by Age Group

  • 12.1. Adult
  • 12.2. Geriatric
  • 12.3. Pediatric

13. Cancer Supportive Care Drugs Market, by Indication

  • 13.1. Bone Metastases Related Events
  • 13.2. Cachexia & Anorexia
  • 13.3. Cancer Pain
  • 13.4. Chemotherapy-Induced Nausea & Vomiting
    • 13.4.1. Acute CINV
    • 13.4.2. Breakthrough/Refractory CINV
    • 13.4.3. Delayed CINV
  • 13.5. Diarrhea
  • 13.6. Mucositis And Stomatitis
  • 13.7. Myelosuppression
    • 13.7.1. Chemotherapy-Induced Anemia
    • 13.7.2. Chemotherapy-Induced Neutropenia

14. Cancer Supportive Care Drugs Market, by Care Setting

  • 14.1. Inpatient
  • 14.2. Outpatient

15. Cancer Supportive Care Drugs Market, by Distribution Channel

  • 15.1. Hospital Pharmacies
  • 15.2. Mail-Order And Online Pharmacies
  • 15.3. Retail Pharmacies
  • 15.4. Specialty Pharmacies

16. Cancer Supportive Care Drugs Market, by End User

  • 16.1. Ambulatory Surgery Centers
  • 16.2. Homecare Settings
  • 16.3. Hospitals
  • 16.4. Oncology Clinics And Infusion Centers

17. Cancer Supportive Care Drugs Market, by Region

  • 17.1. Americas
    • 17.1.1. North America
    • 17.1.2. Latin America
  • 17.2. Europe, Middle East & Africa
    • 17.2.1. Europe
    • 17.2.2. Middle East
    • 17.2.3. Africa
  • 17.3. Asia-Pacific

18. Cancer Supportive Care Drugs Market, by Group

  • 18.1. ASEAN
  • 18.2. GCC
  • 18.3. European Union
  • 18.4. BRICS
  • 18.5. G7
  • 18.6. NATO

19. Cancer Supportive Care Drugs Market, by Country

  • 19.1. United States
  • 19.2. Canada
  • 19.3. Mexico
  • 19.4. Brazil
  • 19.5. United Kingdom
  • 19.6. Germany
  • 19.7. France
  • 19.8. Russia
  • 19.9. Italy
  • 19.10. Spain
  • 19.11. China
  • 19.12. India
  • 19.13. Japan
  • 19.14. Australia
  • 19.15. South Korea

20. United States Cancer Supportive Care Drugs Market

21. China Cancer Supportive Care Drugs Market

22. Competitive Landscape

  • 22.1. Market Concentration Analysis, 2025
    • 22.1.1. Concentration Ratio (CR)
    • 22.1.2. Herfindahl Hirschman Index (HHI)
  • 22.2. Recent Developments & Impact Analysis, 2025
  • 22.3. Product Portfolio Analysis, 2025
  • 22.4. Benchmarking Analysis, 2025
  • 22.5. Abbott Laboratories
  • 22.6. Acacia Pharma Group Plc
  • 22.7. Accord Healthcare Limited
  • 22.8. Amgen Inc.
  • 22.9. APR Applied Pharma Research S.A. by Relief Therapeutics Holding AG
  • 22.10. AstraZeneca plc
  • 22.11. Coherus BioSciences, Inc.
  • 22.12. Daiichi Sankyo Company, Limited
  • 22.13. Dr. Reddy's Laboratories Ltd.
  • 22.14. F. Hoffmann-La Roche Ltd.
  • 22.15. Fresenius Kabi AG
  • 22.16. Fresenius SE & Co. KGaA
  • 22.17. GlaxoSmithKline plc
  • 22.18. Helsinn Healthcare SA
  • 22.19. Heron Therapeutics, Inc.
  • 22.20. Ipsen S.A.
  • 22.21. Johnson & Johnson Services, Inc.
  • 22.22. Lupin Limited
  • 22.23. Novartis AG
  • 22.24. Pfizer Inc.
  • 22.25. Sanofi S.A.
  • 22.26. Teva Pharmaceutical Industries Ltd.
  • 22.27. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORIGINATOR TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CARE SETTING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 15. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 17. CHINA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY 5-HT3 ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY 5-HT3 ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY 5-HT3 ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NK1 ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NK1 ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NK1 ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OLANZAPINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OLANZAPINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OLANZAPINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE-MODIFYING AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE-MODIFYING AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE-MODIFYING AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE-MODIFYING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BISPHOSPHONATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BISPHOSPHONATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BISPHOSPHONATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY RANKL INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY RANKL INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY RANKL INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOPOIETIC AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOPOIETIC AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOPOIETIC AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOPOIETIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DARBEPOETIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DARBEPOETIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DARBEPOETIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY EPOETIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY EPOETIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY EPOETIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MYELOPROTECTION AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MYELOPROTECTION AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MYELOPROTECTION AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THROMBOPOIETIN RECEPTOR AGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THROMBOPOIETIN RECEPTOR AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THROMBOPOIETIN RECEPTOR AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PAIN MANAGEMENT AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PAIN MANAGEMENT AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PAIN MANAGEMENT AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PAIN MANAGEMENT AGENTS, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NON-OPIOIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NON-OPIOIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NON-OPIOIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ACETAMINOPHEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ACETAMINOPHEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ACETAMINOPHEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ADJUVANT ANALGESICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ADJUVANT ANALGESICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ADJUVANT ANALGESICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OPIOIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OPIOIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY LEUKEMIAS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY LEUKEMIAS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY LEUKEMIAS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY LYMPHOMAS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY LYMPHOMAS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY LYMPHOMAS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY GASTROINTESTINAL CANCERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY GASTROINTESTINAL CANCERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY GASTROINTESTINAL CANCERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEAD AND NECK CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEAD AND NECK CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEAD AND NECK CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OVARIAN CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OVARIAN CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY RECTAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY RECTAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY RECTAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORIGINATOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BIOSIMILAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BIOSIMILAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BIOSIMILAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE METASTASES RELATED EVENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE METASTASES RELATED EVENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE METASTASES RELATED EVENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CACHEXIA & ANOREXIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CACHEXIA & ANOREXIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CACHEXIA & ANOREXIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA & VOMITING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA & VOMITING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA & VOMITING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA & VOMITING, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ACUTE CINV, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ACUTE CINV, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ACUTE CINV, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BREAKTHROUGH/REFRACTORY CINV, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BREAKTHROUGH/REFRACTORY CINV, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BREAKTHROUGH/REFRACTORY CINV, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DELAYED CINV, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DELAYED CINV, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DELAYED CINV, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DIARRHEA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DIARRHEA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DIARRHEA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MUCOSITIS AND STOMATITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MUCOSITIS AND STOMATITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MUCOSITIS AND STOMATITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MYELOSUPPRESSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MYELOSUPPRESSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MYELOSUPPRESSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MYELOSUPPRESSION, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED ANEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED ANEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED ANEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INPATIENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INPATIENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OUTPATIENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OUTPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MAIL-ORDER AND ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MAIL-ORDER AND ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 199. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MAIL-ORDER AND ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 202. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY SPECIALTY PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 205. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY SPECIALTY PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 208. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 211. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 212. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 214. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ONCOLOGY CLINICS AND INFUSION CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 217. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ONCOLOGY CLINICS AND INFUSION CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 218. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ONCOLOGY CLINICS AND INFUSION CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 219. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 220. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 221. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 222. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2032 (USD MILLION)
  • TABLE 223. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE-MODIFYING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 224. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOPOIETIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 225. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 226. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PAIN MANAGEMENT AGENTS, 2018-2032 (USD MILLION)
  • TABLE 227. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 228. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 230. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 231. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 232. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORIGINATOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 234. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 235. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA & VOMITING, 2018-2032 (USD MILLION)
  • TABLE 236. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MYELOSUPPRESSION, 2018-2032 (USD MILLION)
  • TABLE 237. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 238. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 239. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 242. NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE-MODIFYING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 244. NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOPOIETIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 246. NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PAIN MANAGEMENT AGENTS, 2018-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 248. NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 250. NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 252. NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORIGINATOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 254. NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA & VOMITING, 2018-2032 (USD MILLION)
  • TABLE 256. NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MYELOSUPPRESSION, 2018-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 258. NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 260. LATIN AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 262. LATIN AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE-MODIFYING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 264. LATIN AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOPOIETIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 266. LATIN AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PAIN MANAGEMENT AGENTS, 2018-2032 (USD MILLION)
  • TABLE 267. LATIN AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 268. LATIN AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 270. LATIN AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 272. LATIN AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORIGINATOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 274. LATIN AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA & VOMITING, 2018-2032 (USD MILLION)
  • TABLE 276. LATIN AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MYELOSUPPRESSION, 2018-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 278. LATIN AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 279. LATIN AMERICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2032 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE-MODIFYING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOPOIETIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PAIN MANAGEMENT AGENTS, 2018-2032 (USD MILLION